4.1 Review

World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2014.961931

关键词

Dementia; guidelines; Alzheimer's disease; Lewy body disease; anti-dementia drugs; neuropsychiatric symptoms

资金

  1. Lundbeck
  2. AstraZeneca
  3. Teva
  4. GlaxoSmithKline
  5. Eli Lilly
  6. Pfizer
  7. Roche
  8. Bristol-Myers Squibb
  9. CSC
  10. Janssen Pharmaceutica
  11. MSD
  12. Novartis
  13. Organon
  14. Pierre Fabre
  15. Schwabe
  16. Sepracor
  17. Servier
  18. Wyeth
  19. Janssen Cilag
  20. Otsuka
  21. NIH [P50 AG05142, R01 AG033288, R01 AG037561]
  22. State of California
  23. Alzheimer's Association
  24. Baxter
  25. Genentech
  26. Johnson Johnson
  27. Abbvie Laboratories
  28. AC Immune
  29. Allon
  30. Biogen Idec
  31. Biotie
  32. Ela
  33. EnVivo
  34. Merck
  35. Piramal
  36. Sanofi
  37. Takeda
  38. Tau Rx
  39. Toyama
  40. Zinfandel
  41. Dainippon Sumitomo Pharma Co Ltd
  42. National Institute for Health Research [NF-SI-0512-10033] Funding Source: researchfish

向作者/读者索取更多资源

Objective. To define a practice guideline for biological treatment of dementias for general practitioners in primary care. Methods. TThis paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care (Ihl et al. 2011). The recommendations were developed by a task force of international experts in the field and are based on randomized controlled studies. Results. Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatric symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatric symptoms, medications should only be considered when psychosocial interventions are not adequate and aft er cautious risk-benefit analysis. Conclusions. Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据